scholarly journals Molecular Classification of Diffuse Gliomas

2021 ◽  
Author(s):  
Kanwalpreet Kaur
Keyword(s):  
Patient Management ◽  
Who Classification ◽  
Clinical History ◽  
Molecular Classification ◽  
Cns Tumors ◽  
Prognostic Information ◽  
Oligodendroglial Tumors ◽  
Idh Mutations ◽  
Diffuse Gliomas

In 2016 WHO classification of CNS tumors genotypic and phenotypic parameters were integrated to define a new nomenclature of diffuse gliomas on the basis of presence or absence of isocitrate dehydrogenase mutations. This resulted in more homogenous and narrowly defined categories with better accuracy of prognostic information, thus, playing a crucial role in patient management. Broadly, astrocytomas are now histologically and genetically distinct with IDH-mutant, ATRX-mutant, 1p/19q-intact and oligodendroglial tumors has IDH-mutant, ATRX-wildtype and 1p/19q-codeleted profile. Glioblastoma are now classified into primary and secondary on the basis of IDH mutations independent of clinical history.

Áp dụng hóa bảng phân loại của ST GALLEN 2013 trong phân nhóm phân tử ung thư vú biểu mô tuyến vú

2020 ◽  
Author(s):  
Chu Nguyen Van
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Molecular Classification ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Prognostic Information ◽  
Patient Groups

Molecular classification of breast cancer is target to category patient groups who need to treat by the appropriate adjuvant therapy and provide more exact prognostic information. Purpose: Determining the proportion of molecular types and commenting on some association with clinicpathological characteristics of breast cancer. Methods: 521 operated breast cancer patients were stained by immunohistochemistry with markes such as: ER, PR, HER2, and Ki67 for classifying into 5 molecular categories and follow up assessment. Results: Type LUMBH- accounted for the highest proportion of 26.5%, followed by luminal A (22.5%). Typically, LUMA was the highest rate in good NPI (35.0%), whereas in poor NPI group, HER2 type was the highest rate (36.4%) (p<0.001). The LUMBH - group has the OS rate during the 5-year follow-up of 94.6% and LUMA is 93.5%; In contrast, the HER2 group showed the lowest OS ratio (72.6%) (p<0.05). Conclusion: Molecular classification of breast cancer according to St Gallen 2013 classification can provide the important information for treatment and prognosis.

Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results

2017 ◽  
Vol 69 ◽  
pp. 15-22 ◽  
Author(s):  
Leomar Y. Ballester ◽  
Jason T. Huse ◽  
Guilin Tang ◽  
Gregory N. Fuller
Keyword(s):  
Molecular Classification ◽  
Diffuse Gliomas

The New WHO Classification of CNS Tumors

1995 ◽  
Vol 2 (3) ◽  
pp. 195-207 ◽  
Author(s):  
Ho-Keung Ng ◽  
Suet-Yi Leung
Keyword(s):  
Who Classification ◽  
Cns Tumors

The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas

2017 ◽  
Vol 137 (1) ◽  
pp. 181-189 ◽  
Author(s):  
Te Whiti Rogers ◽  
Gurvinder Toor ◽  
Katharine Drummond ◽  
Craig Love ◽  
Kathryn Field ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Who Classification ◽  
Central Nervous System Tumours ◽  
Diffuse Gliomas

scholarly journals PATH-21. CLINICAL UTILITY OF DNA METHYLATION PROFILING FOR DIAGNOSIS OF CHALLENGING CENTRAL NERVOUS SYSTEM TUMORS: THE TORONTO EXPERIENCE

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi147-vi147
Author(s):  
Shirin Karimi ◽  
Jeffrey Zuccato ◽  
Yasin Mamatjan ◽  
Sheila Mansouri ◽  
Suganth Suppiah ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Central Nervous System ◽  
Nervous System ◽  
Clinical Utility ◽  
Cns Tumors ◽  
Cns Tumor ◽  
Dna Methylation Profiling ◽  
Diffuse Gliomas ◽  
Methylation Profiling

Abstract The update on the WHO classification of central nervous system (CNS) tumors incorporated molecular signatures for a more accurate diagnosis. Recently, DKFZ has demonstrated the utility of DNA methylation profiling(MP) for molecular classification of CNS tumors. We performed a prospective clinical study over the last three years to evaluate the clinical utility ofDNA MP on FFPE samples of 66 challenging CNS tumor cases using online DKFZ classifier. Eleven samples were excluded due to low tumor DNA content or low calibration(predictive) scores(CS)< 0.3.DNA MP confirmed the original pathology diagnoses in 15(27%)cases. The integrated molecular diagnoses were changed in 38/55(70%) including establishment of a new diagnostic entity, change in molecular signature and subtyping. TheWHO grades were changed in 16(27%) of the tumors; about two-thirds resulted in upgrading. We detected non-canonical IDH mutations in 9 diffuse gliomas and the CNV plots revealed false positive FISH results for 1p/19q co-deletion in two diffuse gliomas. The CNV plots contributed to the final diagnosis in 40(72%) patients. The molecular subtypes of medulloblastoma, ependymoma and glioblastoma subclasses were determined in 36(65%) cases. Seventy-five percent of cases with confirmation of initial diagnosis or change in molecular diagnosis had CS > 0.5, among which 51% had a CS >0.9. The median and range CS of cases with new diagnostic entity and confirmed cases were 0.86(0.37–0.99) and 0.98(0.42–0.99), respectably. Furthermore, we detected higher CS in IDH-mutant gliomas in comparison to glioblastoma IDH-wild type(P=0.04). We also observed lower CS in mesenchymal glioblastoma in comparison to other subclasses. The MGMT promoter methylation was determined in 17/20(85%) glioblastoma cases. While the DKFZ group established CS of 0.9 as a cut-off for matching to methylation classes, our findings suggest lower threshold values in challenging CNS tumor cases. Our experience indicates clinical utility of MP of challenging CNS tumors as a reliable ancillary diagnostic tool in routine neuropathology practice.

scholarly journals Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations

2017 ◽  
Vol 19 (12) ◽  
pp. 1640-1650 ◽  
Author(s):  
John C DeWitt ◽  
Justin T Jordan ◽  
Matthew P Frosch ◽  
Wesley R Samore ◽  
A John Iafrate ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Cost Effectiveness ◽  
Who Classification ◽  
Diffuse Gliomas ◽  
The Central Nervous System ◽  
Classification Of Tumors
Sign in / Sign up

Export Citation Format

Share Document